ClinicalTrials.gg

Program

tozorakimab

Also written as “Tozorakimab”, “MEDI3506” and “Tozorakimab Dose Regimen 1”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Asthma · Respiratory Distress Syndrome · Bronchitis, Chronic · Diabetic Nephropathies, led by AstraZeneca.

Furthest: phase 3, since Dec 2, 202114 company-led studies, 3 open or runningNext primary completion: Jun 7, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca143 open or runningphase 3since Dec 2, 2021Mar 1, 2017Jun 7, 2027phase 2 · NCT06932263
  • Named in AstraZeneca’s own pipeline as tozorakimab, phase 4, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 1, 2017First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT03096795 · 88 enrolled · United Kingdom
  2. Nov 4, 20192 phase 2 studiesNCT04212169, NCT04170543
  3. Aug 7, 2020Phase 2 study in AsthmaNCT04570657 · 250 enrolled · United States, Argentina, Germany and more
  4. Oct 20, 2020Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT04631016 · 137 enrolled · United States, Australia, Canada and more
  5. Jul 27, 2021Phase 1 study in Healthy VolunteerNCT05070312 · 39 enrolled · China
  6. Dec 2, 20212 phase 3 studies in Pulmonary Disease, Chronic ObstructiveNCT05158387, NCT05166889
  7. Nov 11, 2022Phase 3 study in Respiratory Distress SyndromeNCT05624450 · 3,527 planned · United States, Argentina, Australia and more
  8. Aug 25, 2023Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT06040086 · 1,454 enrolled · United States, Argentina, Belgium and more
  9. Mar 5, 2024Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT06304961 · 46 enrolled · Germany
  10. Mar 18, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT06897748 · 98 enrolled · Russia
  11. Apr 1, 2025Phase 2 study in AsthmaNCT06932263 · 540 planned · United States, Argentina, Brazil and more
  12. Apr 29, 2026Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07566195 · 59 planned · France

Ahead

  1. Jun 7, 2027Primary completion: phase 2 study in AsthmaNCT06932263
  2. Nov 4, 2027Primary completion: phase 3 study in Respiratory Distress SyndromeNCT05624450
  3. Dec 29, 2028Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07566195

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07566195Pulmonary Disease, Chronic Obstructive · France3RecruitingDec 29, 202859
NCT06932263Asthma · United States, Argentina, Brazil and more2RecruitingJun 7, 2027540
NCT06897748Pulmonary Disease, Chronic Obstructive · Russia2CompletedApr 21, 202698
NCT06304961Pulmonary Disease, Chronic Obstructive · Germany1CompletedSep 9, 202446
NCT06040086Pulmonary Disease, Chronic Obstructive · United States, Argentina, Belgium and more3CompletedMar 6, 20261,454
NCT05624450Respiratory Distress Syndrome · United States, Argentina, Australia and more3RecruitingNov 4, 20273,527
NCT05166889Pulmonary Disease, Chronic Obstructive · United States, Argentina, Belgium and more3CompletedJan 19, 20261,132
NCT05158387Pulmonary Disease, Chronic Obstructive · United States, Australia, Brazil and more3CompletedJan 19, 20261,172
NCT05070312Healthy Volunteer · China1CompletedFeb 7, 202239
NCT04631016Pulmonary Disease, Chronic Obstructive · United States, Australia, Canada and more2CompletedMay 30, 2023137
NCT04570657Asthma · United States, Argentina, Germany and more2CompletedDec 12, 2022250
NCT04170543Diabetic Nephropathies · United States, Argentina, Canada and more2CompletedMay 16, 2023609
NCT04212169Dermatitis, Atopic · United States, Australia, Germany and more2CompletedJul 21, 2022148
NCT03096795Pulmonary Disease, Chronic Obstructive · United Kingdom1CompletedSep 30, 201988

How it is read

Names in the registry

  • “Tozorakimab”, 10 entries
  • “MEDI3506”, 5 entries
  • “Tozorakimab Dose Regimen 1”, 1 entry
  • “Tozorakimab Dose Regimen 2”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.